Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

BACKGROUND: Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation — to standard chemotherapy would prolo...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :N Engl J Med
Главные авторы: Stone, Richard M., Mandrekar, Sumithra J., Sanford, Ben L., Laumann, Kristina, Geyer, Susan, Bloomfield, Clara D., Thiede, Christian, Prior, Thomas W., Döhner, Konstanze, Marcucci, Guido, Lo-Coco, Francesco, Klisovic, Rebecca B., Wei, Andrew, Sierra, Jorge, Sanz, Miguel A., Brandwein, Joseph M., de Witte, Theo, Niederwieser, Dietger, Appelbaum, Frederick R., Medeiros, Bruno C., Tallman, Martin S., Krauter, Jürgen, Schlenk, Richard F., Ganser, Arnold, Serve, Hubert, Ehninger, Gerhard, Amadori, Sergio, Larson, Richard A., Döhner, Hartmut
Формат: Artigo
Язык:Inglês
Опубликовано: 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5754190/
https://ncbi.nlm.nih.gov/pubmed/28644114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1614359
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы